Converting everyday observations into clear, actionable patterns is essential for making informed treatment decisions
Real-world data from a Truveta study of over 18,000 patients found that tirzepatide users achieved greater weight loss at 12 months compared to semaglutide users, consistent with the SURMOUNT-5 findings [4]
Other studies published by JACC on Friday showed semaglutide improved symptoms linked to heart failure, inflammation and a host of other functions, as well as reducing deaths among patients who suffer chronic kidney disease
Finally, a new kind of next-generation carrier arising from RBCs has been proposed
Tumor microenvironment-responsive nanoparticles enhance IDO1 blockade immunotherapy by remodeling metabolic immunosuppression, adv
Results vary depending on individual health factors